Abstract:Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was first identified as a chromosomal rearrangement (NPM-ALK fusion gene) in anaplastic large cell lymphoma (ALCL). Alternate EML4-ALK gene translocation has been detected in a subset of non-small cell lung cancers (NSCLC) and single point mutations in ALK have been identified in a subset of neuroblastomas. Whereas expression of ALK is limited in normal adult human tissues, genetic studies indicate that aberrant expression of ALK is a key driver in these tumor types, which highlights ALK as an important potential target in treating human tumors. The high sequence homology of ALK with other members of the insulin receptor superfamily, presents a significant challenge in the design of ALK-selective inhibitors. Here we report the identification of a series of potent compounds that inhibit ALK both in vitro and in vivo, while maintaining >60 and 400-fold selectivity over the highly homologous insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor tyrosine kinase (IRK), respectively. A representative member from this series inhibited the kinase activity of ALK, IGF-1R, and IRK with IC50s of 0.58, 38, and 262 nM, respectively, and inhibited the viability of Karpas-299 and SU-DHL-1 cells (ALCL cell lines expressing NPM-ALK) with IC50s of 32 and 8 nM, respectively. In Karpas-299 cells, inhibition of viability directly correlated with decreased cellular phosphorylation of NPM-ALK. In NCI-H3122 cells, a NSCLC cell line expressing an EML4-ALK fusion gene, a 30 nM concentration of the same compound inhibited EML4-ALK phosphorylation and cell viability by approximately 50%. For cells that do not express ALK, the IC50s for inhibition of proliferation in several control ALCL and NSCLC cell lines were >1000 nM and the IC50 for phosphorylation of IRK in hepatoma H4IIE cells was >10,000 nM. In vivo, daily oral administration of this specific lead compound to mice bearing subcutaneous xenografts of Karpas-299 cells elicited a dose-dependent antitumor effect, with near-complete tumor regression observed at the highest doses of 50 and 100 mg/kg. In rats, oral doses that achieved plasma levels that were efficacious in the Karpas-299 mouse model had no effect on either insulin or glucose levels. In conclusion, these data demonstrate that despite the high sequence homology among members of the insulin receptor superfamily, identification of ALK-selective compounds is possible and supports the clinical evaluation of such compounds in patients with ALK-driven tumors. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 3738.

Discovery of Novel, Orally Bioavailable Pyrimidine Ether-Based Inhibitors of ELOVL1

Elovl1 inhibition reduced very long chain fatty acids in a mouse model of adrenoleukodystrophy

Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis in Vivo.

Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)

Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy

Discovery of N-((3r,4r)-4-Fluoro-1-(6-((3-Methoxy-1-Methyl-1h-Pyrazol-4-Yl)Amino)-9-M Ethyl-9h-Purin-2-Yl)Pyrrolidine-3-Yl)Acrylamide (Pf-06747775) Through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic Egfr Mutants with Selectivity over Wild-Type Egfr

Discovery and Optimization of Selective Brain-Penetrant EBP Inhibitors that Enhance Oligodendrocyte Formation

Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase

Discovery of Novel Long‐Chain Alkenyl Diacid Derivatives as ACLY Inhibitors

Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors

Discovery of Cell-Permeable Allosteric Inhibitors of Liver Pyruvate Kinase: Design and Synthesis of Sulfone-Based Urolithins

Lead Optimization of Small Molecule ENL YEATS Inhibitors to Enable In Vivo Studies: Discovery of TDI-11055

Nervonic Acid Attenuates Accumulation of Very Long-Chain Fatty Acids and is a Potential Therapy for Adrenoleukodystrophy

Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma Model

Optimization and Biological Evaluation of Novel 1H-Pyrrolo[2,3-c]pyridin Derivatives As Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia

Discovery of a Novel Series of Inhibitors of Lymphoid Tyrosine Phosphatase with Activity in Human T Cells.

Abstract #3738: Discovery of Potent and Selective Orally Active Inhibitors of Anaplastic Lymphoma Kinase (ALK)

Discovery of Selective Small-Molecule Inhibitors for the ENL YEATS Domain

Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design.